Lv31
374 积分 2021-01-23 加入
When the standard changes during the trial: Reflections on targeted therapy in FGFR2-rearranged cholangiocarcinoma
29分钟前
求助中
ASTRUM-006 and the changing landscape of perioperative therapy for gastric cancer
54分钟前
求助中
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
28天前
已完结
Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
1个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
1个月前
已完结
First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies
1个月前
已完结
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
1个月前
已完结
Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study
1个月前
已关闭
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
1个月前
已完结
The future of blood-based biomarkers in liver cancer
1个月前
已完结
皖公网安备34019202002308
